Home › New Cohorts From CheckMate -012 Assess Optimal Dosing Of Opdivo+Yervoy In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer
 

Keywords :   


New Cohorts From CheckMate -012 Assess Optimal Dosing Of Opdivo+Yervoy In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer

2015-09-08 07:25:25| drugdiscoveryonline Home Page

Bristol-Myers Squibb Company recently announced updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase 1b trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC)

Tags: with advanced cell treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.11PlayStationVitaPCH-2000
23.11GB
23.11 Malbon
23.11PING PEARL GATES
23.11WATCH
23.11L
23.11Tetsuya_SP2 DMC
23.116
More »